Breaking News Instant updates and real-time market news.

TRVN

Trevena

$6.03

0.11 (1.86%)

13:53
10/19/16
10/19
13:53
10/19/16
13:53

Meet Trevena: CEO Gowen expects new clinical trial data in Q1

In an exclusive interview with The Fly, Trevena's (TRVN) CEO Maxine Gowen discussed the company's primary drug candidate Oliceridine, or TRV130, and its ongoing Phase 3 studies: "We are still expecting to share the top line data from both [Oliceridine] APOLLO studies in the first quarter of 2017 as we have guided. Our goal for Oliceridine is a labeled indication for the management of moderate to severe acute pain. So that means any moderate to severe pain when an IV medicine is appropriate and that's regardless of what causes the pain. According to FDA, you can get a broad label like this or this can be supported by demonstrating efficacy in both the hard tissue and the soft tissue pain in the case study. So that's why our Phase 3 program includes bunionectomy, which is a hard tissue model of bone surgery, and an abdominoplasty trial, which is a soft tissue model. We use both of these models in the Phase 2 trials and from that we generated the very compelling data around Oliceridine's efficacy as well as safety and tolerability compared to morphine. So with those two [APOLLO] pivotal trials as well as the multi procedure ATHENA study, which is a trial we're doing, we believe that we'll have sufficient data to support that broad label indication without the need to do any further trials." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.

  • 22

    Oct

  • 13

    Dec

TRVN Trevena
$6.03

0.11 (1.86%)

03/02/16
WBTH
03/02/16
INITIATION
Target $18
WBTH
Buy
Trevena initiated with a Buy at WallachBeth
WallachBeth analyst Caroline Palomeque started Trevena with a Buy rating and $18 price target. The company's lead candidate Oliceridine for post-operative acute pain may offer patients a treatment option with comparable analgesic efficacy, a faster onset of action and a more favorable safety profile than morphine, Palomeque tells investors in a research note.
03/02/16
03/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Chemical Financial (CHFC) initiated with a Strong Buy at Raymond James by analyst David Long, who believes its pending accretive merger with Talmer Bancorp (TLMR) will provide the base for a more profitable company with strengthened growth prospects. 2. Infinity Pharmaceuticals (INFI) initiated with an Outperform at FBR Capital, with analyst Christopher James saying that duvelisib has the potential to be a first-in-class treatment for specific types of blood cancers. 3. Trevena (TRVN) initiated with a Buy at WallachBeth by analyst Caroline Palomeque, who said Oliceridine may offer patients a treatment option with comparable analgesic efficiency, a faster onset of action and a more favorable safety profile than morphine. 4. Aduro Biotech (ADRO) initiated with an Outperform at FBR Capital. 5. LKQ Corp. (LKQ) initiated with a Buy at Sterne Agee CRT. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/29/16
FBRC
03/29/16
INITIATION
Target $16
FBRC
Outperform
Trevena initiated with an Outperform at FBR Capital
FBR Capital analyst Christopher James started Trevena with an Outperform rating and $16 price target.
05/17/16
ROTH
05/17/16
NO CHANGE
Target $14.5
ROTH
Buy
Roth Capital remains a buyer of Trevena
Roth Capital analyst Michael Higgins reiterates a Buy rating and $14.50 price target on Trevena's shares. The analyst says the company announced that its TRV027 failed in Phase 2 and will be discontinuing the program. However, given the relative risk of development between its oliceridine and its TRV027, Higgins is not making any changes to his financial models. Trevena is "well-capitalized," with cash sufficient to fund operations for two years, the analyst tells investors in a research note, adding that he sees the company's shares as being at an "attractive entry point."

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.